Newsmeme!
Discover News you didn't know existed
Francistown — More than 1,000 people from all walks of life thronged Marang Super Spar complex in Francistown on Sunday for eye tests and free reading glasses.
FRANCISTOWN: More than 1,000 people from all walks of life thronged Marang Super Spar complex in Francistown on Sunday for eye tests and free reading glasses. The testing was part of Lions Club International's First Sight programme, a global initiative to fight the major causes of preventable and avoidable blindness.
BARENDRECHT, Netherlands----Optelec, world leader in innovative and life-changing assistive technologies for the visually impaired and blind, announces the new 1X magnification functionality in the flagship Optelec ClearView+ High Definition desktop video magnifier.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal ...
Doctors say more younger diabetics are needing sight-saving treatment for a condition older patients normally develop.
LEUVEN, Belgium, February 9 /PRNewswire/ -- - Paper Examines the Potential of Microplasmin to Improve the Treatment of a Range of Back of the Eye Diseases ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II ...
-
Paloma Pharmaceuticals Inc. Posted on:05 Feb 10 JAMAICA PLAIN, Massachusetts, February 4 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD). The Phase I study, "A Phase I Open-Label Study to Investigate the Safety, Tolerability and ...
pSivida Corp.
Paloma Pharmaceuticals, Inc. announced that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD). The Phase I study, "A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced ...
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |